Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $5.0 million
Deal Type : Funding
Bactolife Receives USD 5 Million in New Funding to Address Gastrointestinal Infections Worldwide
Details : Bactolife™ uses its proprietary Binding Protein™ technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance development as well as the general burden of infe...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : Olitigaltin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients with COVID-19 were able to inhale GB0139 and achieve consistent exposure of GB0139 at levels previously associated with systemic biomarker responses in IPF patients (including YKL-40 and PAI-1).
Product Name : GB0139
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : Olitigaltin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AJ Vaccines To Develop Vaccine for COVID-19
Details : The vaccine candidate will use technology to raise strong immune responses while being well tolerated and to meet potential global demand in 2021.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 03, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The EU Horizon 2020 Consortium
Deal Size : $0.9 million
Deal Type : Funding
ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme
Details : The aim of the grant is to support the consortium in development of a COVID-19 vaccine candidate, including performing a Phase I/IIa clinical trial.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 03, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The EU Horizon 2020 Consortium
Deal Size : $0.9 million
Deal Type : Funding